
For research use only. We do not supply to patients.
For pharmaceutical-grade products or other inquiries, please contact our experts.
Hirudin arrests the growth of ovarian cancer cells (A2780) by disrupting the thrombin–PAR-1–PKCα–EMT axis. Thrombin cleaves the N-terminus of PAR-1, which unveils an N-terminus tethered ligand that auto-activates PAR-1. This recruits Gαq/11 and activates phospholipase Cβ, resulting in the formation of diacylglycerol which phosphorylates PKCα. Phospho-PKCα translocates to the nucleus, where it stabilizes Snail, a master transcriptional repressor of E-cadherin and an activator of CDH2 and Vimentin. Hirudin sterically blocks access to PAR-1. PKCα is unphosphorylated, Snail mRNA rapidly decreases and mesenchymal genes CDH2 and Vimentin are transcriptionally repressed. Loss of these EMT drivers maintain A2780 cells in an epithelial, non-proliferative state.
Hirudin is a specific molecular off-switch for the thrombin-EMT circuit in ovarian cancer cells. These data suggest that Hirudin is worthy of further consideration as an anti-cancer agent for the treatment of ovarian cancer.
Fig. 1 Mechanism of action for Hirudin against ovarian cancer. (Kou J.; et al. 2024)
References
Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed
All our products are chemicals for research purposes only. We do not supply for human or veterinary applications.
Privacy Policy | Cookie Policy Copyright © Protheragen. All Rights Reserved.
